NANOBIOTIX Announces Two Key Additions to its Board of Directors to Further Equip the Company for Long-Term Sustainable Growth Page 1

• Dr. Margaret A. Liu, global expert in vaccines, gene therapy and cancer immunotherapy; CEO of PAX Therapeutics and member of several boards of directors
• Ms. Anat Naschitz, Proven Investor and Entrepreneur in Life Sciences; Co-Founder of OrbiMed Israel

PARIS and CAMBRIDGE, Mass., Sept. 4, 2024 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ”Company”), a late-clinical-stage biotechnology company pioneering nanoparticle therapeutic approaches to expand treatment options for patients with cancer and other serious diseases, today announced the nominations of Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Board of Trustees.

“We are excited to welcome Ms. Anat Naschitz and Dr. Margaret A. Liu to the Nanobiotix Board of Trustees as we continue to leverage the practice-changing potential of nanophysics-based therapies for the treatment of cancer and other serious diseases,” said Laurent Levy, Ph.D., CEO and Chairman of the Board of Nanobiotix. “Dr. Liu brings a wealth of experience in U.S. and international academia, pharmaceuticals, biotechnology and public policy that may prove critical to making Nanobiotix’s vision a reality at this important time in the company’s history. Ms. Naschitz brings a world-class fluency in the language of capital and how that capital can best be deployed to support disruptive innovation for the benefit of patients, healthcare professionals and investors.”